DIET & NUTRITION 
PATIENT EDUCATION 
OBESITY/WEIGHT MANAGEMENT 
EXERCISE/TRAINING 
LEGAL MATTERS 
GUIDELINES/RECOMMENDATIONS 📋 Regulatory Action / Label Change
The FDA granted Priority Review to asundexian, an oral Factor XIa inhibitor, for secondary stroke prevention. The decision rests on the phase 3 OCEANIC-STROKE trial in noncardioembolic ischemic stroke and high-risk TIA.
Clinical Considerations
- In 12,327 patients, asundexian reduced ischemic stroke to 6.2% versus 8.4% on placebo (HR 0.74; 95% CI, 0.65-0.84).
- The composite of cardiovascular death, MI, or stroke fell to 9.2% versus 11.1% (HR 0.83), reinforcing the efficacy signal.
- ISTH major bleeding did not differ significantly (1.9% vs 1.7%; HR 1.10; 95% CI, 0.85-1.44), a notable contrast with existing anticoagulants.
- Eligibility required atherosclerotic features: prior atherosclerosis, nonlacunar infarct, or cerebrovascular plaque on imaging.
Practice Applications
- Recognize Factor XIa inhibition as a mechanism decoupling efficacy from bleeding risk.
- Interpret results within the noncardioembolic, atherosclerotic population studied.
- Monitor the FDA decision and eventual labeling before prescribing.
- Anticipate how asundexian may fit alongside current antiplatelet regimens.
